The firm saw an improvement in progression-free survival for patients on the ivonescimab regimen and a trend toward improved overall survival.

Phase III progression-free survival data were positive for first-line Braftovi in first-line combination therapy for mCRC.

Effect of Metformin Versus Placebo on New Primary Cancers in Canadian ... of pretreatment tumor HER3 membrane expression levels and across diverse mechanisms of EGFR TKI resistance. In patients with ...

Metformin is the most commonly prescribed oral treatment for type 2 diabetes mellitus (T2DM), a condition prevalent in patients with cardiovascular diseases. Since LCZ696 and metformin may be ...